Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy

Peng Liu; Liwei Zhao; Guido Kroemer; Oliver Kepp

doi:10.1080/2162402X.2024.2412874

Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy

Oncoimmunology. 2024 Oct 4;13(1):2412874. doi: 10.1080/2162402X.2024.2412874. eCollection 2024.

Authors

Peng Liu^{1

2}, Liwei Zhao^{1

2}, Guido Kroemer^{1

2

3}, Oliver Kepp^{1

2}

Affiliations

¹ Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.
² Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France.
³ Department of Biology, Institut du Cancer Paris CARPEM, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Abstract

Recent findings revealed that neoantigen-specific cytotoxic type 1 regulatory T (T_R1) CD4 T cells can subvert cancer immunotherapy by killing type 1 conventional dendritic cells (cDC1s) that present tumor antigens bound to MHC class II. This underlines the importance of cDC1s for eliciting anticancer immunity but poses a novel clinical challenge.

Keywords: Immunotherapy; checkpoint inhibitor; immunogenic cell death; monoclonal antibody.

MeSH terms

Animals
Antigens, Neoplasm / immunology
Dendritic Cells* / immunology
Humans
Immunotherapy* / methods
Neoplasms* / immunology
Neoplasms* / therapy
T-Lymphocytes, Regulatory* / immunology

Substances

Antigens, Neoplasm

Grants and funding

Parts of the figures have been created with BioRender.com. O.K. receives funding by Association pour la recherche sur le cancer (ARC) and Institut National du Cancer (INCa). G.K. is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; ARC; Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen (ANR 21-ESRE-0028); European Joint Programme on Rare Diseases (EJPRD); European Research Council Advanced Investigator Award (ERC-2021-ADG, ICD-Cancer, Grant No. 101052444), European Union Horizon 2020 Projects Oncobiome, Prevalung (grant No. 101095604) and Crimson (No. 101016923); Fondation Carrefour; INCa; Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Immunolife; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM).